title: Evolving role of SPECT/CT in neuroendocrine tumors management: staging, treatment response, and follow-up.
abstract: The combined use of SPECT and CT strongly supports the molecular imaging of neuroendocrine tumors (NETs) with somatostatin receptor radiopharmaceuticals or with meta-iodobenzylguanidine. SPECT/CT fusion images provide potential attenuation correction, higher specificity, and accurate localization for the staging, evaluation of treatment response, and follow-up of NETs.
authors.affiliation: From the *Nuclear Medicine Unit, Fondazione Salvatore Maugeri, Pavia, Italy; †Service of Nuclear Medicine, Department of Nuclear Medicine, PET/CT Centre, Radiology, Neuroradiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo, Italy; and ‡Department of Radiology, University of Southern California, Los Angeles, CA.
authors.forename: Chiara
authors.initials: C
authors.lastname: Fuccio
authors.forename: Elena Giulia
authors.initials: EG
authors.lastname: Spinapolice
authors.forename: Sotirios
authors.initials: S
authors.lastname: Chondrogiannis
authors.forename: Anna Margherita
authors.initials: AM
authors.lastname: Maffione
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Trifirò
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Colletti
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome